Sundhedsudvalget 2020-21
SUU Alm.del Bilag 251
Offentligt
2329709_0001.png
Invitation to participate in the 3
rd
EU HCV Policy
Virtual Summit on the elimination of Hepatitis C
in Europe Securing Wider EU Commitment to the
elimination of HCV 24 March 2021 2pm – 6pm
Dear Mr Nielsen
On behalf of the Hepatitis B and C Public Policy Association we have the pleasure to
invite you to participate in the Association’s upcoming
European Policy
Summit
dedicated to the elimination of the hepatitis C virus (HCV) in Europe entitled
Securing Wider EU Commitment to the Elimination of HCV.
As a champion of the
healthcare sector and given your commitment to shaping the policy agenda to
improve patients’ lives, we would be delighted if you could join.
The Summit,
which is organised in partnership with leading patient and professional associations,
will be held virtually on the
24th March 2021, between 2pm and 6pm.
Despite the progress that has been made in recent years, HCV remains a major
public health problem in Europe. In the European Union (EU) more people die each
year from HCV than from HIV/AIDS. The latest data for the WHO European Region
shows an estimated 15 million people have hepatitis C, which equates to 2.0% of all
adults. When the elimination strategy was published in May 2016, the World Health
Organization (WHO) estimated that more than 7 million lives would be saved
worldwide by 2030, if targets were achieved. However, according to recent European
Centre for Disease Prevention and Control (ECDC) findings, only a few European
countries have met the 2020 target of the European Action Plan in diagnosing 50% of
people with chronic hepatitis B or C.
In the context of strained healthcare systems and shifting priorities, largely as a result
of the COVID-19 crisis, it is essential to ensure that the importance of efforts to
SUU, Alm.del - 2020-21 - Bilag 251: Invitation til 3rd EU HCV Policy Virtual Summit on the elimination of Hepatitis C in Europe
2329709_0002.png
eliminate HCV is not forgotten. If anything, the current pandemic should underline the
need for widespread and effective public health responses. Often referred to as a
“silent pandemic” as patients often have no symptoms during the first 20-30
years,
HCV must continue to be a priority for decision makers.
This planned half-day Summit aims to bring together policymakers, experts, members
of parliament, mayors, patient associations, and clinicians from across Europe, to
raise awareness on the state of play regarding the goal of elimination of HCV by
2030. It will also showcase best practices as well as indicate what policy actions are
needed to get more countries on track to achieve HCV elimination by 2030.
The 2021 EU HCV Policy Summit will provide an exceptional opportunity for
participants to:
Review the progress made in the last five years to understand how far Europe
is from achieving the goal of eliminating HCV by 2030
Exchange views on the role and state of diagnosis, treatment and care
Evaluate the impact of the COVID-19 crisis on the HCV epidemic
Share national-level
best practice and discuss EU’s position as a leader in
helping deliver the elimination target
You can find more information about the Summit on the conference website
www.hcvbrusselssummit.eu
We very much hope that you will be able to spare some time from your busy agenda
to accept our invitation. You can register your interest in the Summit through the
event’s
Eventbrite page.
Once you have registered, details on how to access the
Summit’s online platform will be sent closer to the date of the event.
Please do not hesitate to contact me or Ms Ann Fox at the Summit Secretariat
SUU, Alm.del - 2020-21 - Bilag 251: Invitation til 3rd EU HCV Policy Virtual Summit on the elimination of Hepatitis C in Europe
2329709_0003.png
([email protected]) should you have any questions.
Yours sincerely,
Prof. Angelos Hatzakis MD PhD
Co-Chair Hepatitis B & C Public Policy Association
Professor of Epidemiology and Preventive Medicine, Athens University Medical
School
Prof. Georgios Papatheodoridis, MD PhD
Treasurer, Hepatitis B&C Public Policy Association
Professor in Medicine & Gastroenterology, Athens University Medical School
Prof. Heiner Wedemeyer, MD
Co-Chair Hepatitis B&C Public Policy Association
Chairman Department of Gastroenterology, Hepatology and Endocrinology Hannover
Medical School